Commentary

Video

Dr Patel on the Importance of Real-World Data in Lung Cancer Treatment

Sandip P. Patel, MD, discusses the 2023 Bridging the Gaps in Lung Cancer meeting, expanding on the continued importance of replicating clinical trial approaches in the real-world setting.

Sandip P. Patel, MD, medical oncologist, professor, medicine, University of California, San Diego (UCSD), UCSD Health, discusses the 2023 Bridging the Gaps in Lung Cancer meeting, expanding on the continued importance of replicating clinical trial approaches in the real-world setting.

It is a well-established fact that clinical practice guidelines often mirror high-level evidence, Patel begins. However, the introduction of novel therapies and targets into the medical landscape necessitates a more dynamic approach, according to Patel. Real-world decision-making requires a consensus among specialists who have direct, hands-on experience managing these diseases, he explains. The Bridging the Gaps meeting aimed to facilitate such consensus-building, forging common ground among experts to address and navigate these intricate and atypical clinical situations that regularly present in thoracic oncology, Patel emphasizes.

The spectrum of topics covered in the conference were diverse, spanning from early detection strategies to the management of clinical challenges that currently lack definitive solutions, he continues. One such challenge explored was the scenario of patients who receive neoadjuvant chemoimmunotherapy but do not achieve a pathologic complete remission, Patel explains. The optimal course of action in these cases was deliberated, underlining the pressing need for guidance in this area, he notes. The meeting also delved into the realm of advanced therapies and considerations for second-line treatment and beyond, specifically addressing the intricate issue of brain metastases, Patel says.

A key takeaway from the meeting is the continued importance of asking more purposeful questions, Patel emphasizes. As the realm of thoracic oncology continues to evolve, asking the right questions becomes pivotal in the endeavor to facilitate patient care, he explains. Framing inquiries in an informative manner empowers health care professionals to enhance patient outcomes, according to Patel. The conference underscored its commitment to aiding both patients and the dedicated physicians who grapple with the intricacies of managing a diverse array of cancer types, Patel concludes.

Related Videos
Jonathan Spicer, MD, PhD, FRCS
Daniel DeAngelo, MD, PhD
Marc J. Braunstein, MD, PhD, associate professor, Department of Medicine, co-director, Hematology-Oncology System, New York University (NYU) Grossman Long Island School of Medicine
Douglas W. Sborov, MD, MS, associate professor, Department of Internal Medicine—Division of Hematology and Hematologic Malignancies; director, Hematology Disease Center and Plasma Cell Dyscrasias Program, the University of Utah Huntsman Cancer Institute
Bradley C. Carthon, MD, PhD
David C. Fisher, MD
Alan Tan, MD
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss unmet needs and future research directions in ALK-positive and ROS1-positive NSCLC.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss data for lorlatinib in ROS1-positive NSCLC after crizotinib and chemotherapy.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss data for taletrectinib in ROS1-positive advanced non–small cell lung cancer.